{"title":"Unmasking disparities in bladder cancer outcomes in the disaggregated Asian American population.","authors":"Wenjin An, Dong Shen, Dan Li, Jie Shen","doi":"10.1080/14737140.2025.2556884","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Research on urothelial carcinoma of the bladder (UCUB) in non-Hispanic Asian American (NHAA) populations typically amalgamate all subgroups, masking significant intra-ethnic difference. This study aimed to examine variations in UCUB characteristics and outcomes within NHAA populations.</p><p><strong>Research design and methods: </strong>Patients with UCUB were identified from the Surveillance, Epidemiology, and End Results database. The NHAA cohort disaggregated into Chinese, Filipino, South Asian, Japanese, Korean, Vietnamese, and other Asian subgroups. Kaplan-Meier and Cox proportional hazards models were used to estimate unadjusted and adjusted overall survival (OS) and cancer-specific survival (CSS).</p><p><strong>Results: </strong>NHAA patients (<i>n</i> = 2,686) exhibited the longest median OS (88 months) compared to other cohorts (<i>p</i> < 0.001). Among NHAA subgroups, five-year OS rates ranged from 50% in Filipino patients to 64% in other Asian groups. In adjusted analyses, Chinese (HR 0.84, 95% CI 0.74-0.94), Korean (HR 0.74, 95% CI 0.61-0.91), and other Asian (HR 0.68, 95% CI 0.56-0.82) patients exhibited significantly reduced mortality risk relative to Non-Hispanic White patients.</p><p><strong>Conclusions: </strong>Filipino Americans faced comparatively poorer survival, while Chinese and Korean Americans showed more favorable prognoses. These findings highlight the need for targeted, culturally tailored interventions and refined risk stratification to enhance equity in the management of UCUB.</p>","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-10"},"PeriodicalIF":2.8000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2556884","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Research on urothelial carcinoma of the bladder (UCUB) in non-Hispanic Asian American (NHAA) populations typically amalgamate all subgroups, masking significant intra-ethnic difference. This study aimed to examine variations in UCUB characteristics and outcomes within NHAA populations.
Research design and methods: Patients with UCUB were identified from the Surveillance, Epidemiology, and End Results database. The NHAA cohort disaggregated into Chinese, Filipino, South Asian, Japanese, Korean, Vietnamese, and other Asian subgroups. Kaplan-Meier and Cox proportional hazards models were used to estimate unadjusted and adjusted overall survival (OS) and cancer-specific survival (CSS).
Results: NHAA patients (n = 2,686) exhibited the longest median OS (88 months) compared to other cohorts (p < 0.001). Among NHAA subgroups, five-year OS rates ranged from 50% in Filipino patients to 64% in other Asian groups. In adjusted analyses, Chinese (HR 0.84, 95% CI 0.74-0.94), Korean (HR 0.74, 95% CI 0.61-0.91), and other Asian (HR 0.68, 95% CI 0.56-0.82) patients exhibited significantly reduced mortality risk relative to Non-Hispanic White patients.
Conclusions: Filipino Americans faced comparatively poorer survival, while Chinese and Korean Americans showed more favorable prognoses. These findings highlight the need for targeted, culturally tailored interventions and refined risk stratification to enhance equity in the management of UCUB.
期刊介绍:
Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches.
Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care.
Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections:
Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results
Article Highlights – an executive summary of the author’s most critical points.